Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-Use, By Type, And Segment Forecasts, 2023-2030

1.1 Market Segmentation & Scope
1.1.1 Product Life Cycle
1.1.2 Service Provider
1.1.3 Type
1.1.4 Process Flow
1.1.5 Therapeutic Area
1.1.6 End-Use
1.1.7 Regional Scope
1.1.8 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research:
1.3.5 Details Of Primary Research
1.3.5.1 Data For Primary Interviews In North America
1.3.5.2 Data For Primary Interviews In Europe
1.3.5.3 Data For Primary Interviews In Apac
1.3.5.4 Data For Primary Interviews In Latin America
1.3.5.5 Data For Primary Interviews In Mea
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Top Down Market Estimation
1.6.1.2 Cagr Calculation
1.6.1.3 Key Report Updates
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Market Definitions
1.10 Report Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:

2.1 Market Snapshot
2.2 Segment Snapshot (Product Life Cycle & Service Provider)
2.3 Segment Snapshot (Type & Therapeutic Area)
2.4 Segment Snapshot (Process Flow & End Use)
2.5 Competitive Landscape Snapshot

3.1 Market Lineage Outlook
3.1.1 Parent Market Analysis
3.1.2 Ancillary Market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing Drug Consumption And Drug Development Rates
3.3.1.2 Increasing Incidence Of Adr And Drug Toxicity
3.3.1.3 Increasing Trend Of Outsourcing Pharmacovigilance Services
3.3.1.4 Increasing Externalization Of Clinical Trial Studies By Large Pharmaceutical And Biopharmaceutical Companies
3.3.1.5 Increasing Regulatory Burden On Manufacturers
3.3.1.6 Introduction Of Technologically Advanced Software Services
3.3.1.7 Constantly Rising Investment On R&D By Healthcare Companies
3.3.1.8 Partnerships And Collaborations Between Market Players
3.3.2 Market Restraint Analysis
3.3.2.1 Shortage Of Skilled Labor
3.3.2.2 Expensive Technology For Small And Mid-Sized Player
3.3.2.3 Lack Of Recognition
3.3.2.4 Scarcity Of Integration Standards
3.3.3 Industry Challenges
3.4 Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Value Chain Analysis
3.6.1 Preclinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle against Service Offering and Their Demand
3.8 Regulatory Framework
3.8.1 List Of Regulatory Bodies By Country
3.9 Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug Safety Budget Allocation By Activities
3.10.2 By Development Phase
3.10.3 By Therapeutic Area
3.10.4 Pricing Level
3.10.4.1 Project Management
3.10.4.2 Case Processing
3.10.4.3 Adr Reporting
3.10.4.4 Medical Writing
3.10.4.5 Drug Safety Management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature Screening
3.11.1.3 Automation And Ai
3.11.1.4 Big Data Analytics In Pv
3.12 Impact Of Covid-19
3.12.1 Recent Developments & Strategic Outcomes
3.12.1.1 Regulatory Requirements/Changes Due To Covid-19
3.12.2 Strategies Implemented By Companies
3.12.2.1 Iqvia
3.12.2.2 Paraxel International Corporation
3.12.2.3 Bioclinica
3.12.2.4 Pharmaceutical Product Development (Ppd)
3.12.2.5 Ibm Corporation
3.12.2.6 Icon, Plc
3.12.2.7 Pra Health Sciences
3.12.2.8 Covance Inc
3.12.2.9 Arisglobal
3.12.2.10 Linical Accelovance
3.12.2.11 Laboratory Corporation Of America Holdings
3.13 Market Trends
3.13.1 Scaling Of Resources
3.13.2 Automation In Pharmacovigilance
3.14 Impact Of Inflation
3.15 Comparative Analysis Between Medical Writing Vs Medical Safety Review
3.15.1 Medical Writing Market Outlook, 2022
3.15.1.1 Medical Writing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
3.15.2 Medical Safety Review Market Outlook, 2022
3.15.2.1 Medical Safety Review Market Estimates And Forecasts, 2018 - 2030 (USD Million)

4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
4.2 Product Life Cycle Dashboard
4.3 Market Definition And Scope
4.3.1 Preclinical
4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.2 PHASE I
4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.3 PHASE II
4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.4 PHASE III
4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.5 PHASE IV
4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

5.1 Service provider Market Share Analysis, 2022 & 2030
5.2 Service Provider Dashboard
5.3 Market definition and scope
5.3.1 In House
5.3.1.1 In House Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.2 Contract Outsourcing
5.3.2.1 Contract Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.1 Type Market Share Analysis, 2022 & 2030
6.2 Type Dashboard
6.3 Market definition and scope
6.3.1 Spontaneous Reporting
6.3.1.1 Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2 Intensified Adr Reporting
6.3.2.1 Intensified Adr Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3 Targeted Spontaneous Reporting
6.3.3.1 Targeted Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4 Cohort Event Monitoring (CEM)
6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.5 EHR Mining
6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

7.1 Process Flow Market Share Analysis, 2022 & 2030
7.2 Process Flow Dashboard
7.3 Market definition and scope
7.3.1 Case Data Management
7.3.1.1 Case Data Management Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.1.1.1 Case Logging
7.3.1.1.1.1 Case Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.1.1.2 Case data analysis
7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.1.1.3 Medical reviewing and reporting
7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.2 Signal Detection
7.3.2.1 Signal Detection Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.1 Adverse Event Logging
7.3.2.1.1.1 Adverse Event Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.2 Adverse Event Analysis
7.3.2.1.2.1 Adverse Event Analysis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2.1.3 Adverse Event Review & Reporting
7.3.2.1.3.1 Adverse Event Review & Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3 Risk Mamangement System
7.3.3.1 Risk Management System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3.1.1 Risk Evaluation System
7.3.3.1.1.1 Risk Evaluation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3.1.2 Risk Mitigation System
7.3.2.1.2.1 Risk Mitigation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)

8.1 Therapeutic Area Market Share Analysis, 2022 & 2030
8.2 Therapeutic Area Dashboard
8.3 Market definition and scope
8.3.1 Oncology
8.3.1.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.2 Neurology
8.3.2.1 Neurology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.3 Cardiology
8.3.3.1 Cardiology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.4 Respiratory Systems
8.3.4.1 Respiratory Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.5 Others
8.3.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

9.1 End-Use Market Share Analysis, 2022 & 2030
9.2 End-Use Dashboard
9.3 Market definition and scope
9.3.1 Pharmacuticals
9.3.1.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 Biotechnology Companies
9.3.2.1 Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.3 Medical Device Manufacturers
9.3.3.1 Medical Device Manufacturers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.4 Others
9.3.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

10.1 Regional Market Snapshot
10.2 North America
10.2.1 North America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.2.2 U.S.
10.2.2.1 U.S. Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
10.2.2.2 Competitive Scenario
10.2.2.3 Regulatory Framework
10.2.3 Canada
10.2.3.1 Canada Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.2.3.2 Competitive Scenario
10.2.3.3 Regulatory Framework
10.3 Europe
10.3.1 Europe Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.2 UK
10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030(USD Million)
10.3.2.2 Competitive scenario
10.3.2.3 Regulatory Framework
10.3.3 Germany
10.3.3.1 Germany Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million
10.3.3.2 Competitive Scenario
10.3.3.3 Regulatory Framework
10.3.4 France
10.3.4.1 France Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
10.3.4.2 Competitive Scenario
10.3.4.3 Regulatory Framework
10.3.5 Italy
10.3.5.1 Italy Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.5.2 Competitive Scenario
10.3.5.3 Regulatory Framework
10.3.6 Spain
10.3.6.1 Spain Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.3.6.2 Competitive Scenario
10.3.6.3 Regulatory Framework
10.3.7 Russia
10.3.7.1 Russia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
10.3.7.2 Competitive Scenario
10.3.7.3 Regulatory Framework
10.3.8 Denmark
10.3.8.1 Denmark Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
10.3.8.2 Competitive Scenario
10.3.8.3 Regulatory Framework
10.3.9 Norway
10.3.9.1 Norway Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
10.3.9.2 Competitive Scenario
10.3.9.3 Regulatory Framework
10.3.10 Sweden
10.3.10.1 Sweden Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
10.3.10.2 Competitive Scenario
10.3.10.3 Regulatory Framework
10.4 Asia Pacific
10.4.1 Asia Pacific Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.2 Japan
10.4.2.1 Japan Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.2.2 Competitive Scenario
10.4.2.3 Regulatory Framework
10.4.3 China
10.4.3.1 China Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.3.2 Competitive Scenario
10.4.3.3 Regulatory Framework
10.4.4 India
10.4.4.1 India Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.4.2 Competitive Scenario
10.4.4.3 Regulatory Framework
10.4.5 Australia
10.4.5.1 Australia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.5.2 Competitive Scenario
10.4.5.3 Regulatory Framework
10.4.6 Thailand
10.4.6.1 Thailand Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.6.2 Competitive Scenario
10.4.6.3 Regulatory Framework
10.4.7 South Korea
10.4.7.1 South Korea Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.7.2 Competitive Scenario
10.4.7.3 Regulatory Framework
10.5 Latin America
10.5.1 Latin America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.2.2 Competitive Scenario
10.5.2.3 Regulatory Framework
10.5.3 Mexico
10.5.3.1 Mexico Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.3.2 Competitive Scenario
10.5.3.3 Regulatory Framework
10.5.4 Argentina
10.5.4.1 Argentina Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.4.2 Competitive Scenario
10.5.4.3 Regulatory Framework
10.6 MEA
10.6.1 MEA Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.2 South Africa
10.6.2.1 South Africa Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.2.2 Competitive Scenario
10.6.2.3 Regulatory Framework
10.6.3 Saudi Arabia
10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
10.6.3.2 Competitive Scenario
10.6.3.3 Regulatory Framework
10.6.4 UAE
10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
10.6.4.2 Competitive Scenario
10.6.4.3 Regulatory Framework
10.6.5 Kuwait
10.6.5.1 Kuwait Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
10.6.5.2 Competitive Scenario
10.6.5.3 Regulatory Framework

11.1 Market Participation Categorization
11.2 Public Companies
11.2.1 Company Market Position Analysis
11.2.2 Company Market Share
11.3 Private Companies
11.3.1 List Of Key Emerging Companies
11.4 Increasing strategic collaborations and product launch
11.5 Strategic Government initiatives which include collaborations
11.6 Competitors increased PV awareness program
11.7 Competitors increased collaboration and outsourcing of operations
11.8 Consolidation Trends
11.9 Potential Customers

12.1 Company Profiles
12.1.1 ACCENTURE
12.1.1.1 Company overview
12.1.1.2 Service benchmarking
12.1.1.3 Financial performance
12.1.1.4 Strategic initiatives
12.1.1.5 SWOT Analysis
12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
12.1.2.1 Company overview
12.1.2.2 Service benchmarking
12.1.2.3 Financial performance
12.1.2.4 Strategic initiatives
12.1.2.5 SWOT Analysis
12.1.3 IQVIA
12.1.3.1 Company overview
12.1.3.2 Service benchmarking
12.1.3.3 Financial performance
12.1.3.4 Strategic initiatives
12.1.3.5 SWOT Analysis
12.1.4 COGNIZANT
12.1.4.1 Company overview
12.1.4.2 Service benchmarking
12.1.4.3 Financial performance
12.1.4.4 Strategic initiatives
12.1.4.5 SWOT Analysis
12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
12.1.5.1 Company overview
12.1.5.2 Service benchmarking
12.1.5.3 Financial performance
12.1.5.4 Strategic initiatives
12.1.5.5 SWOT Analysis
12.1.6 IBM CORPORATION
12.1.6.1 Company overview
12.1.6.2 Service benchmarking
12.1.6.3 Financial performance
12.1.6.4 Strategic initiatives
12.1.6.5 SWOT Analysis
12.1.7 ARISGLOBAL
12.1.7.1 Company overview
12.1.7.2 Service benchmarking
12.1.7.3 Financial performance
12.1.7.4 Strategic initiatives
12.1.7.5 SWOT Analysis
12.1.8 ICON PLC.
12.1.8.1 Company overview
12.1.8.2 Service benchmarking
12.1.8.3 Financial performance
12.1.8.4 Strategic initiatives
12.1.8.5 SWOT Analysis
12.1.9 CAPGEMINI
12.1.9.1 Company overview
12.1.9.2 Service benchmarking
12.1.9.3 Financial performance
12.1.9.4 Strategic initiatives
12.1.9.5 SWOT Analysis
12.1.10 ITCLINICAL
12.1.10.1 Company overview
12.1.10.2 Service benchmarking
12.1.10.3 Financial performance
12.1.10.4 Strategic initiatives
12.1.10.5 SWOT Analysis
12.1.11 TAKE SOLUTIONS LIMITED
12.1.11.1 Company overview
12.1.11.2 Service benchmarking
12.1.11.3 Financial performance
12.1.11.4 Strategic initiatives
12.1.11.5 SWOT Analysis
12.1.12 PAREXEL INTERNATIONAL CORPORATION.
12.1.12.1 Company overview
12.1.12.2 Service benchmarking
12.1.12.3 Financial performance
12.1.12.4 Strategic initiatives
12.1.12.5 SWOT Analysis
12.1.13 BIOCLINICA, INC.
12.1.13.1 Company overview
12.1.13.2 Service benchmarking
12.1.13.3 Financial performance
12.1.13.4 Strategic initiatives
12.1.13.5 SWOT Analysis
12.1.14 WIPRO
12.1.14.1 Company overview
12.1.14.2 Service benchmarking
12.1.14.3 Financial performance
12.1.14.4 Strategic initiatives
12.1.14.5 SWOT Analysis
12.1.15 UNITED BIOSOURCE LLC
12.1.15.1 Company overview
12.1.15.2 Service benchmarking
12.1.15.3 Financial performance
12.1.15.4 Strategic initiatives
12.1.15.5 SWOT Analysis
12.1.16 FMD K&L (CLINCHOICE)
12.1.16.1 Company overview
12.1.16.2 Service benchmarking
12.1.16.3 Financial performance
12.1.16.4 Strategic initiatives
12.1.16.5 SWOT Analysis

13.1 Key Winning/Scoring Criteria
13.1.1 BY Categories
13.1.1.1 Pharmaceuticals
13.1.1.2 Biotech companies
13.1.1.3 Medical device companies
13.2 Key Vendor Selection Factors
13.2.1 BY Category
13.2.2 By Company Size
13.2.2.1 Key Takeways

Table 1: List of secondary sources
Table 2: List of Abbreviation
Table 3: Types of ADRs
Table 4: Adverse Drug Events (ADEs) in hospitals
Table 5: Pharmacovigilance outsourcing services insights
Table 6: List of regulations, by country
Table 7: Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 8: Case management costing by year
Table 9: Price by case processing volume
Table 10: Subscription services for medical manuscript writing
Table 11: Total literature searches (2013-2022)
Table 12: Instances of failed phase I clinical trials for COVID-19 vaccine
Table 13: Recruiting phase II clinical trials for oncology
Table 14: Outsourcing trend observed in pharmaceutical companies
Table 15: Recent Market Events
Table 16: List of Major Deals & Acquisitions
Table 17: North America pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 18: North America pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 19: North America pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 20: North America pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 21: North America pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 22: North America pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 23: U.S. pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 24: U.S. pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 25: U.S. pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 26: U.S. pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 27: U.S. pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 28: U.S. pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 29: Canada pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 30: Canada pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 31: Canada pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 32: Canada pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 33: Canada pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 34: Canada pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 35: Europe pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 36: Europe pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 37: Europe pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 38: Europe pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 39: Europe pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 40: Europe pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 41: UK pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 42: UK pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 43: UK pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 44: UK pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 45: UK pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 46: UK pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 47: Germany pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 48: Germany pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 49: Germany pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 50: Germany pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 51: Germany pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 52: Germany pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 53: France pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 54: France pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 55: France pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 56: France pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 57: France pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 58: France pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 59: Italy pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 60: Italy pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 61: Italy pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 62: Italy pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 63: Italy pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 64: Italy pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 65: Spain pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 66: Spain pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 67: Spain pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 68: Spain pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 69: Spain pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 70: Spain pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 71: Russia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 72: Russia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 73: Russia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 74: Russia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 75: Russia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 76: Russia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 77: Denmark pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 78: Denmark pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 79: Denmark pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 80: Denmark pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 81: Denmark pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 82: Denmark pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 83: Norway pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 84: Norway pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 85: Norway pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 86: Norway pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 87: Norway pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 88: Norway pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 89: Sweden pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 90: Sweden pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 91: Sweden pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 92: Sweden pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 93: Sweden pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 94: Sweden pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 95: Asia Pacific pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 96: Asia Pacific pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 97: Asia Pacific pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 98: Asia Pacific pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 99: Asia Pacific pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 100: Asia Pacific pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 101: Japan pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 102: Japan pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 103: Japan pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 104: Japan pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 105: Japan pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 106: Japan pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 107: China pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 108: China pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 109: China pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 110: China pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 111: China pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 112: China pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 113: India pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 114: India pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 115: India pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 116: India pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 117: India pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 118: India pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 119: Australia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 120: Australia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 121: Australia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 122: Australia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 123: Australia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 124: Australia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 125: Thailand pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 126: Thailand pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 127: Thailand pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 128: Thailand pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 129: Thailand pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 130: Thailand pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 131: South Korea pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 132: South Korea pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 133: South Korea pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 134: South Korea pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 135: South Korea pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 136: South Korea pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 137: Latin America pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 138: Latin America pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 139: Latin America pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 140: Latin America pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 141: Latin America pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 142: Latin America pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 143: Brazil pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 144: Brazil pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 145: Brazil pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 146: Brazil pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 147: Brazil pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 148: Brazil pharmacovigilance market, by end use, 2017- 2030 (USD Million
Table 149: Mexico pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 150: Mexico pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 151: Mexico pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 152: Mexico pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 153: Mexico pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 154: Mexico pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 155: Argentina pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 156: Argentina pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 157: Argentina pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 158: Argentina pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 159: Argentina pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 160: Argentina pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 161: MEA pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 162: MEA pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 163: MEA pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 164: MEA pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 165: MEA pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 166: MEA pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 167: South Africa pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 168: South Africa pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 169: South Africa pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 170: South Africa pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 171: South Africa pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 172: South Africa pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 173: Saudi Arabia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 174: Saudi Arabia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 175: Saudi Arabia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 176: Saudi Arabia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 177: Saudi Arabia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 178: Saudi Arabia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 179: UAE pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 180: UAE pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 181: UAE pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 182: UAE pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 183: UAE pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 184: UAE pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 185: Kuwait pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 186: Kuwait pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 187: Kuwait pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 188: Kuwait pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 189: Kuwait pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 190: Kuwait pharmacovigilance market, by end use, 2018-2030 (USD Million)

Fig. 1: Pharmacovigilance market segmentation
Fig. 2: Market research process
Fig. 3: Data triangulation techniques
Fig. 4: Primary research pattern
Fig. 5: Primary interviews in North America
Fig. 6: Primary interviews in Europe
Fig. 7: Primary interviews in APAC
Fig. 8: Primary interviews in Latin America
Fig. 9: Primary interviews in MEA
Fig. 10: Market research approaches
Fig. 11: Value-chain-based sizing & forecasting
Fig. 12: QFD modeling for market share assessment
Fig. 13: Market formulation & validation
Fig. 14: Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Fig. 15: Market Snapshot
Fig. 16: Segment Snapshot (Product Life Cycle & Service Provider)
Fig. 17: Segment Snapshot (Type & Therapeutic Area)
Fig. 18: Segment Snapshot (Process Flow & End Use))
Fig. 19: Competitive Landscape Snapshot
Fig. 20: Penetration & growth prospect mapping
Fig. 21: Pharmacovigilance market dynamics
Fig. 22: Porter’s five force model
Fig. 23: Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 24: Pharmacovigilance & Patient Safety Services - Product Life Cycle
Fig. 25: PV department
Fig. 26: PV organization structure
Fig. 27: Estimated budget allocation of drug safety activities at global and country-level
Fig. 28: Comparison between estimated global and country-level drug safety budget allocation
Fig. 29: Average % of drug safety budget contributed by function at a global level
Fig. 30: Pharmacovigilance system cost for small-sized firms and larger-sized firms
Fig. 31: Clinical trial cost by phase (%)
Fig. 32: Selected clinical trials costs based on technology
Fig. 33: Estimated cost of developing therapeutic medical device in the U.S.
Fig. 34: The average monthly cost of illness due to ADRs
Fig. 35: Medical Writers Employers by Industry
Fig. 36: Trending topics on social media (2017)
Fig. 37: ADR detection and from social media data
Fig. 38: Common literature automation tool flow
Fig. 39: Automation processes in PV
Fig. 40: Deterrents to Leveraging the Cloud (Oracle Survey)
Fig. 41: The three-step process to compute signal statistics from search log using big data
Fig. 42: Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Fig. 43: Pharma & Biotech R&D expense growth, 2020 (%)
Fig. 44: Medical writing market outlook, 2022 (USD Million)
Fig. 45: Medical writing market, 2018-2030 (USD Million)
Fig. 46: Global medical safety review market, 2018-2030 (USD Million)
Fig. 47: Pharmacovigilance market: Product life cycle movement analysis
Fig. 48: Pharmacovigilance market product life cycle dashboard
Fig. 49: Global Preclinical market, 2018-2030 (USD Million)
Fig. 50: Global Phase I market, 2018-2030 (USD Million)
Fig. 51: Global Phase II market, 2018-2030 (USD Million)
Fig. 52: Global Phase III market, 2018-2030 (USD Million)
Fig. 53: Adverse events reported in FAERS system, 2019-2022
Fig. 54: Global Phase IV market, 2018-2030 (USD Million)
Fig. 55: Pharmacovigilance market: Service provider movement analysis
Fig. 56: Pharmacovigilance Service provider dashboard
Fig. 57: Global In-house market, 2018-2030 (USD Million)
Fig. 58: Global contract outsourcing market, 2018-2030 (USD Million)
Fig. 59: Pharmacovigilance market: Type movement analysis
Fig. 60: Pharmacovigilance type dashboard
Fig. 61: Global spontaneous reporting market, 2018-2030 (USD Million)
Fig. 62: Global intensified ADR reporting market, 2018-2030 (USD Million)
Fig. 63: Global targeted spontaneous reporting market, 2018-2030 (USD Million)
Fig. 64: Global CEM market, 2018-2030 (USD Million)
Fig. 65: Global EHR mining market, 2018-2030 (USD Million)
Fig. 66: Pharmacovigilance market: Process flow movement analysis
Fig. 67: Pharmacovigilance market process flow dashboard
Fig. 68: Global case data management market, 2018-2030 (USD Million)
Fig. 69: Global case logging market, 2018-2030 (USD Million)
Fig. 70: Global case data analysis market, 2018-2030 (USD Million)
Fig. 71: Global medical reviewing and reporting market, 2018-2030 (USD Million)
Fig. 72: Global signal detection market, 2018-2030(USD Million)
Fig. 73: Global adverse event logging market, 2018-2030 (USD Million)
Fig. 74: Global adverse event analysis market, 2018-2030 (USD Million)
Fig. 75: Global adverse event review & reporting market, 2018-2030 (USD Million)
Fig. 76: Global risk management system market, 2018-2030 (USD Million)
Fig. 77: Global Risk Evaluation System market, 2018-2030 (USD Million)
Fig. 78: Global risk mitigation system market, 2018-2030 (USD Million)
Fig. 79: Pharmacovigilance market: Therapeutic area movement analysis
Fig. 80: Pharmacovigilance market therapeutic area dashboard
Fig. 81: Global oncology market, 2018-2030 (USD Million)
Fig. 82: Global neurology market, 2018-2030 (USD Million)
Fig. 83: Global cardiology market, 2018-2030 (USD Million)
Fig. 84: Global respiratory systems market, 2018-2030 (USD Million)
Fig. 85: Global others market, 2018-2030 (USD Million)
Fig. 86: Pharmacovigilance market: End-use movement analysis
Fig. 87: Pharmacovigilance market end-use dashboard
Fig. 88: Global pharmaceuticals market, 2018-2030 (USD Million)
Fig. 89: Global biotechnology companies’ market, 2018-2030 (USD Million)
Fig. 90: Global medical device manufacturers market, 2018-2030 (USD Million)
Fig. 91: Global others market, 2018-2030 (USD Million)
Fig. 92: Regional market place: Key takeaways
Fig. 93: North America pharmacovigilance market, 2018- 2030 (USD Million)
Fig. 94: U.S. key country dynamics
Fig. 95: U.S. key country dynamics
Fig. 96: U.S. pharmacovigilance market, 2018-2030(USD Million)
Fig. 97: Canada key country dynamics
Fig. 98: Canada key country dynamics
Fig. 99: Canada pharmacovigilance market, 2018-2030 (USD Million)
Fig. 100: Europe pharmacovigilance market, 2018-2030 (USD Million)
Fig. 101: UK key country dynamics
Fig. 102: UK key country dynamics
Fig. 103: UK pharmacovigilance market, 2018-2030 (USD Million)
Fig. 104: Germany key country dynamics
Fig. 105: Germany key country dynamics
Fig. 106: Germany pharmacovigilance market, 2018-2030 (USD Million)
Fig. 107: France key country dynamics
Fig. 108: France key country dynamics
Fig. 109: France pharmacovigilance market, 2018-2030 (USD Million)
Fig. 110: Italy key country dynamics
Fig. 111: Italy key country dynamics
Fig. 112: Italy pharmacovigilance market, 2018-2030 (USD Million)
Fig. 113: Spain key country dynamics
Fig. 114: Spain key country dynamics
Fig. 115: Spain pharmacovigilance market, 2018-2030 (USD Million)
Fig. 116: Russia key country dynamics
Fig. 117: Russia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 118: Denmark key country dynamics
Fig. 119: Denmark key country dynamics
Fig. 120: Denmark pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 121: Norway key country dynamics
Fig. 122: Norway key country dynamics
Fig. 123: Norway pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 124: Sweden key country dynamics
Fig. 125: Sweden key country dynamics
Fig. 126: Sweden pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 127: Asia Pacific Pharmacovigilance market, 2018-2030 (USD Million)
Fig. 130: Japan pharmacovigilance market, 2018-2030 (USD Million)
Fig. 131: China key country dynamics
Fig. 132: China key country dynamics
Fig. 133: China pharmacovigilance market, 2018-2030 (USD Million)
Fig. 134: India key country dynamics
Fig. 135: India key country dynamics
Fig. 136: India pharmacovigilance market, 2018-2030 (USD Million)
Fig. 139: Australia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 140: Thailand key country dynamics
Fig. 141: Thailand key country dynamics
Fig. 142: Thailand pharmacovigilance market, 2018-2030 (USD Million)
Fig. 145: South Korea pharmacovigilance market, 2018-2030 (USD Million)
Fig. 146: Latin America pharmacovigilance market, 2018-2030 (USD Million)
Fig. 149: Brazil pharmacovigilance market, 2018-2030 (USD Million)
Fig. 150: Mexico key country dynamics
Fig. 152: Mexico pharmacovigilance market, 2018-2030 (USD Million)
Fig. 155: Argentina pharmacovigilance market, 2018-2030 (USD Million)
Fig. 156: MEA pharmacovigilance market, 2018-2030 (USD Million)
Fig. 159: South Africa pharmacovigilance market, 2018-2030 (USD Million)
Fig. 162: Saudi Arabia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 163: UAE key country dynamics
Fig. 164: UAE key country dynamics
Fig. 165: UAE pharmacovigilance market, 2018-2030 (USD Million)
Fig. 167: Kuwait pharmacovigilance market, 2018-2030 (USD Million)
Fig. 168: Market participant categorization
Fig. 169: Company market position analysis
Fig. 170: Estimated company market share analysis, 2022 (%)
Fig. 171: SWOT - Accenture
Fig. 172: SWOT - Linical Americas
Fig. 173: SWOT - IQVIA
Fig. 174: SWOT - Cognizant
Fig. 175: SWOT - Laboratory Corporation of America Holdings
Fig. 176: SWOT - IBM Corporation
Fig. 177: SWOT - ArisGlobal
Fig. 178: SWOT - ICON plc
Fig. 179: SWOT - Capgemini
Fig. 180: SWOT - ITClinical
Fig. 181: SWOT - Take Solutions
Fig. 182: SWOT - Parexel International Corporation
Fig. 183: SWOT - Clario
Fig. 184: SWOT - Wipro
Fig. 185: SWOT - United BioSource LLC
Fig. 186: SWOT - FMD K&L
Fig. 187: Commonly outsourced PV activities
Fig. 188: Vendor selection criteria